Compare Ascendis Pharma A/S (ASND) vs Twilio Inc (TWLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Twilio Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Twilio Inc trades at $215.82 (market cap $32.56B). The key difference: Twilio Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| ASND | TWLO | |
|---|---|---|
Market Cap | $17.74B | $32.56B |
Sector | Health | Technology |
52-Week High | $277.18 | $236.64 |
52-Week Low | $163.32 | $92.44 |
Enterprise Value | $18.11B | $31.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Twilio trades at $214.56, down 1.85% on the day, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows improving fundamentals with revenue growth to $5.07B in 2025 and a return to net profitability. Recent earnings beats and positive analyst sentiment, including a Goldman Sachs buy initiation at $300 (June 24, 2026), highlight momentum in AI-driven cloud communications.
Outlook remains positive given strong earnings beats and margin expansion potential, but high valuation multiples (P/E 325.09) pose risks if growth slows. Investors face execution risks in competitive SaaS markets and sensitivity to tech sector volatility. Wall Street consensus is bullish with 75% buy ratings and a $215.14 price target, near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
